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Summary
 
Human herpesvirus 6 (HHV-6) is a potentially immunosuppressive agent that may act as a co-
factor in the progression of AIDS. Here, we describe the first small animal model of HHV-6 in-
fection. HHV-6 subgroup A, strain GS, efficiently infected the human thymic tissue implanted
in SCID-hu Thy/Liv mice, leading to the destruction of the graft. Viral DNA was detected in
Thy/Liv implants by quantitative polymerase chain reaction (PCR) as early as 4 d after inocu-
lation and peaked at day 14. The productive nature of the infection was confirmed by electron
microscopy and immunohistochemical staining. Atypical thymocytes with prominent nu-
clear inclusions were detected by histopathology. HHV-6 replication was associated with
severe, progressive thymocyte depletion involving all major cellular subsets. However, intra-
thymic T progenitor cells (ITTPs) appeared to be more severely depleted than the other sub-
populations, and a preferred tropism of HHV-6 for ITTPs was demonstrated by quantitative
PCR on purified thymocyte subsets. These findings suggest that thymocyte depletion by HHV-6
may be due to infection and destruction of these immature T cell precursors. Similar results
were obtained with strain PL-1, a primary isolate belonging to subgroup B. The severity of the
lesions observed in this animal model underscores the possibility that HHV-6 may indeed be
immunosuppressive in humans.
Key words: thymus gland • acquired immunodeficiency syndrome • T lymphocyte subsets • 
flow cytometry • polymerase chain reaction
 
H
 
uman herpesvirus 6 (HHV-6)
 
1
 
 is a ubiquitous 
 
b
 
-herpes-
virus, first isolated from immunocompromised pa-
tients with various forms of lymphoproliferative disorders (1).
All HHV-6 isolates can be classified into two subgroups, A
and B. The B subgroup is predominant in the human popula-
tion; it is associated with most of the cases of 
 
exanthem subitum
 
in children, and its prevalence in healthy adults is almost uni-
versal. In contrast, no disease has been definitively linked to
subgroup A, and its prevalence is still largely unknown. Be-
cause most of the A isolates have been derived from immu-
nocompromised patients, this virus has been suggested to play
a role in immunodeficiency, including AIDS (2).
HHV-6 has a primary tropism for mature CD4
 
1
 
 T cells,
both in vitro (3) and in vivo (4), and can also productively
infect mature CD8
 
1
 
 T cells, NK cells, 
 
g
 
/
 
d
 
 T cells (2), and
thymocytes (3). HHV-6 exerts marked cytopathic effects in
all of these cell types, suggesting that it may cause immuno-
suppression by infecting and destroying T cells or their pre-
cursors. Recently, HHV-6 has been implicated as a cause
of severe progressive immunodeficiency in an HIV-1–sero-
negative infant (5). The patient had thymic atrophy and
severe T lymphocytopenia associated with extensive HHV-6
infection of the thymus and lymph nodes.
Several lines of evidence suggest that HHV-6 may also
function as a cofactor in AIDS, accelerating the progression
towards the full-blown disease. In vitro studies have shown
several positive interactions between HHV-6 and HIV-1,
 
Some of the results in this manuscript were presented at the Annual Meet-
ing of the Institute of Human Virology, Baltimore, MD, August 1998.
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including the ability of HHV-6 to productively coinfect
CD4
 
1
 
 T lymphocytes with HIV-1, resulting in an enhanced
cytopathic effect (6). HHV-6 can induce de novo expres-
sion of CD4 on cells that physiologically do not express it,
such as mature CD8
 
1
 
 T cells, NK cells, and 
 
g
 
/
 
d
 
 T cells,
rendering them susceptible to HIV-1 infection (6). In vivo
data indicate that HHV-6 infection is active and wide-
spread in symptomatic HIV-infected patients (7–9), but de-
finitive evidence of the immunosuppressive capability of
HHV-6 and of its role in AIDS is still lacking.
One of the limitations hampering the elucidation of the
pathogenic role of HHV-6 is that no reliable animal models
of infection and pathogenesis by HHV-6 have been estab-
lished to date, despite preliminary evidence indicating that
the nonhuman primate 
 
Macaca nemestrina
 
 is susceptible to
HHV-6 infection both in vitro (2) and in vivo (9a). SCID-hu
Thy/Liv mice, obtained by coimplanting human fetal liver
and thymus into immunodeficient SCID mice, are a well-
established model for studying the pathogenesis of human
viruses in vivo (10–18). After coimplantation under the
murine kidney capsule, the human fetal tissues fuse, vascu-
larize, and grow into a unique “Thy/Liv” organ that is
morphologically and functionally equivalent to the human
thymus (19, 20). This organ can be infected with human
viruses by direct intrathymic injection. Thy/Liv implants
are composed of five main thymocyte subpopulations that
represent progressive stages of thymocyte maturation (21).
The first stage is represented by a rare population with a
triple-negative phenotype (CD3
 
2
 
CD4
 
2
 
CD8
 
2
 
). Some of
these cells differentiate into intrathymic T progenitor cells
(ITTPs), which display a CD3
 
2
 
CD4
 
1
 
CD8
 
2
 
 phenotype.
This rapidly dividing population, which constitutes 
 
z
 
1–2%
of the total thymocyte population, subsequently differenti-
ates into CD3
 
2
 
CD4
 
1
 
CD8
 
1
 
 and CD3
 
1
 
CD4
 
1
 
CD8
 
1
 
 dou-
ble-positive (DP) thymocytes. DP thymocytes are the most
abundant subpopulation in Thy/Liv implants, accounting
for 
 
z
 
80–85% of total thymocytes. Most of the DP thymo-
cytes die within the thymus, but a fraction differentiates into
mature CD3
 
1
 
CD4
 
1
 
CD8
 
2
 
 single-positive 4 (SP4) and CD3
 
1
 
CD4
 
2
 
CD8
 
1
 
 single-positive 8 (SP8) thymocytes. Specific
tropisms of varicella zoster virus (16) and HIV-1 (11, 12, 14,
22) for different subpopulations of human thymocytes have
been shown in SCID-hu Thy/Liv mice.
In this paper, we describe the effects of HHV-6 infection
on the human thymus in SCID-hu Thy/Liv mice, focusing
on the prototype HHV-6 subgroup A, strain GS (HHV-
6A
 
GS
 
). This strain was found to replicate efficiently in Thy/
Liv implants and to induce severe depletion of thymocytes,
supporting the hypothesis that it may act as an immunosup-
pressive agent in vivo. Similar results were obtained using
HHV-6B
 
PL-1
 
, a primary isolate belonging to subgroup B.
 
Materials and Methods
 
Inoculation of SCID-hu Thy/Liv Mice with HHV-6.
 
SCID-hu
Thy/Liv mice were obtained by coimplanting small pieces of hu-
man second trimester fetal liver and thymus under the kidney
capsule of male homozygous CB-17 
 
scid/scid
 
 (SCID) mice (20).
Thy/Liv implants were infected 4–7 mo after implantation, as
described (23). In brief, mice were anesthetized, the left kidney
was surgically exposed, and the implant was inoculated with 25–
50 
 
m
 
l of viral stock with a titer of 10
 
5
 
 (strain GS) or 10
 
4
 
 (strain
PL-1) 50% tissue culture infectious doses (TCID
 
50
 
) per 50 
 
m
 
l.
UV-inactivated viral stock and culture medium were used for
mock inoculations. The abdominal wall incision was sutured, and
the skin was closed with staples. All procedures and practices
were approved by the University of California, San Francisco
Committee on Human Research or by the University of Califor-
nia, San Francisco Committee on Animal Research.
HHV-6A
 
GS
 
, a primary subgroup A isolate, was obtained from
cultures of purified human cord blood CD4
 
1
 
 T cells infected
with cell-free viral stock at a multiplicity of infection of 0.5. At
day 6 after infection, the supernatants were collected, centrifuged
at 2,500 
 
g
 
, and stored at 
 
2
 
80
 
8
 
C. HHV-6B
 
PL-1
 
, a primary sub-
group B isolate, was obtained from in vitro–activated peripheral
blood cells of a healthy adult blood donor and propagated for a
single passage in activated cord blood CD4
 
1
 
 T cells. No HHV-7
contamination was detected by nested PCR assay, and the stocks
were also negative for 
 
Mycoplasma
 
. Virus titration was performed
by infecting triplicate cultures of phytohemagglutinin-activated
human peripheral blood mononuclear cells with serial 10-fold di-
lutions of the viral stock.
 
Collection of Thy/Liv Implants from SCID-hu Mice.
 
SCID-hu
mice were killed by CO
 
2
 
 inhalation, and implants were removed
at different times after inoculation. Implants were processed for
histopathology and electron microscopy as detailed below. For
cytofluorimetric analysis, cell sorting, and quantitative PCR, sin-
gle-cell suspensions were obtained by grinding the implants in a
nylon bag. The cells were counted in a Coulter counter and di-
vided into aliquots for the different assays.
 
Histology and Immunohistochemistry.
 
Thy/Liv implants were fixed
in 10% buffered formalin, embedded in paraffin, cut into 4-
 
m
 
m-
thick sections, and stained with hematoxylin and eosin (H&E).
For immunohistochemistry, unstained sections were pretreated
with trypsin and pronase. The sections were then stained with a
polyclonal antibody specific for CD3 (Dako) or an mAb specific
for CD68 (Dako), using a standard peroxidase-labeled streptavidin-
biotin (LSAB-peroxidase) method (LSAB2; Dako), followed by
visualization with diaminobenzidine (DAB) and CuSO
 
4
 
 en-
hancement (24). Before the second phase of staining, the samples
were denatured in 2 N HCl for 10 min. The sections were then
stained with 9A5D12, an mAb specific for the p41 early protein
of HHV-6 (25). This antibody was revealed by a standard LSAB-
alkaline phosphatase method (LSAB2; Dako) followed by visual-
ization with Vector Red (Vector Laboratories). Negative controls
included purified nonimmune mouse or rabbit serum (Dako),
followed by LSAB-peroxidase staining. The sections were then
denatured in HCl, and LSAB-alkaline phosphatase staining was
carried out after incubation with either mouse serum (no stain) or
9A5D12 (red staining only).
 
Electron Microscopy.
 
Small pieces of Thy/Liv implants were
fixed in 2.5% glutaraldehyde, and samples were postfixed in os-
mium tetroxide, dehydrated in 2,2-dimethoxypropane, and em-
bedded in Poly/Bed 812 resin (Polysciences, Inc.). Thin sections
(600–900 Å) were cut with a diamond knife, mounted on copper
grids, stained with uranyl acetate and lead citrate, and examined
on a JEOL 100 SX electron microscope.
 
Cytofluorimetric Analysis and Cell Sorting.
 
Single-cell suspensions
were stained with an mAb cocktail containing CD4-FITC (Bec-
ton Dickinson), CD8-PE (Becton Dickinson), and CD3-tricolor
 1955
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(CD3-TC) (Caltag). Cells were washed, resuspended in PBS
containing 1% paraformaldehyde, and analyzed on a FACScan
 
®
 
(Becton Dickinson) for CD4, CD8, and CD3 expression after
gating on a live-cell lymphoid population identified by forward-
and side-scatter characteristics. For cell sorting, unfixed cells were
stained as for FACS
 
® 
 
analysis. A FACS Vantage™ (Becton Dick-
inson) was used to purify four populations of thymocytes: CD3
 
1
 
CD4
 
1
 
CD8
 
2
 
 (SP4), CD3
 
1
 
CD4
 
2
 
CD8
 
1
 
 (SP8), CD3
 
1
 
CD4
 
1
 
CD8
 
1
 
(DP), and CD3
 
2
 
CD4
 
1
 
CD8
 
2
 
 (ITTP). Sorted cells were frozen as
dry pellets and stored at 
 
2
 
80
 
8
 
C for DNA extraction.
 
Quantitative PCR.
 
DNA was extracted from frozen pellets by
proteinase K digestion and purified by phenol-chloroform ex-
traction by standard techniques. Viral load was quantitated with
the TaqMan
 
®
 
 fluorogenic detection system on an ABI Prism
7700 Sequence Detector
 
®
 
 (Perkin-Elmer Applied Biosystems [26]).
PCR was performed with primers 5
 
9
 
-CAAAGCCAAATTATC-
CAGAGCG-3
 
9
 
 and 5
 
9
 
-CGCTAGGTTGAGGATGATCGA-3
 
9
 
and a probe located in the highly conserved open reading frame
U67 of HHV-6 (27): 5
 
9
 
-CACCAGACGTCACACCCGAAG-
GAAT-3
 
9
 
. PCR amplification consisted of denaturation at 95
 
8
 
C
for 15 min, followed by 40 cycles of denaturation at 95
 
8
 
C for 15 s
and annealing/extension at 58
 
8
 
C for 60 s (Locatelli, G., F. San-
toro, A. Gobbi, F. Veglia, P. Lusso, and M. Malnati, manuscript
in preparation).
 
Statistical Analysis.
 
Nonparametric statistical analyses were per-
formed using the Mann-Whitney U test (StatView 5.0; Abacus
Concepts).
 
Results
 
Replication of HHV-6A
 
GS
 
 in Human Thy/Liv Implants.
 
58 SCID-hu Thy/Liv mice from 6 different cohorts, each
made with tissues from a single fetal donor, were inocu-
lated with HHV-6 by direct intrathymic injection of 10
 
5
 
TCID
 
50
 
 of strain GS or mock infected with UV-inactivated
viral stock or with cell culture medium. Mice were killed 4,
7, 11, 14, and 27 d after inoculation, and the implants were
removed. Viral replication was monitored by quantitative
PCR on total thymocyte suspensions with the TaqMan
 
®
real time detection system. HHV-6 DNA was detected as
early as 4 d after inoculation in each of the three implants
examined (Fig. 1). The viral load peaked on day 14 with a
mean value of z6,000 copies/103 cells. In the implants
harvested 27 d after inoculation, a drastic reduction in the
number of genomic copies, with a mean of z400 copies/
103 cells, was observed (Fig. 1). No HHV-6 DNA was de-
tected in the mock-infected control implants. The produc-
tive nature of HHV-6AGS infection in Thy/Liv implants was
demonstrated by transmission electron microscopy showing
viral particles at different stages of maturation (Fig. 2). In
particular, naked viral nucleocapsids were observed in the nu-
cleus, tegument-coated particles in the cytoplasm (not shown),
Figure 1. Replication of HHV-6AGS in
Thy/Liv implants. Implants were harvested
4, 7, 11, 14, and 27 d after direct intrathy-
mic injection with HHV-6AGS or mock in-
jection of UV-inactivated viral stock (n 5
9) or culture medium (n 5 12) (Mock).
Data obtained at day 4, 7, and 11 were
pooled. The amount of HHV-6 DNA and
cell yield per implant are shown as means 6
SEM. The numbers in parentheses indicate
the number of mice analyzed at each of the
indicated time points. Results include three
independent experiments with six different
cohorts of SCID-hu Thy/Liv mice. *P ,
0.01, ‡P , 0.001 vs. mock; §P , 0.05 vs.
days 4–11, and P , 0.001 vs. day 27.
Figure 2. Transmission electron microscopy of a Thy/Liv implant har-
vested 11 d after inoculation with HHV-6AGS. Naked viral nucleocapsids
are visible in the nucleus, and two mature virions are visible in a cytoplas-
mic vacuole (insert). Original magnifications: 310,000; inset, 340,000.
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and mature, enveloped virions in cytoplasmic vacuoles. This
pattern is consistent with the documented ultrastructural de-
velopment of HHV-6 in cells infected in vitro (28).
Thymocyte Depletion and Histopathological Changes in Thy/
Liv Implants Infected with HHV-6AGS. HHV-6AGS infection
of Thy/Liv implants was associated with a marked, pro-
gressive depletion of thymocytes (Fig. 1). The number of
thymocytes harvested from the HHV-6AGS–infected im-
plants was significantly reduced at day 14 (P , 0.01) com-
pared with mock-infected implants and was reduced by
.98% by day 27 (P , 0.001). A representative HHV-
6AGS–infected Thy/Liv implant is shown in Fig. 3 A.
Compared with the mock-infected implant shown in Fig.
3 B, the HHV-6AGS–infected thymus had a marked expan-
sion of the medullary zone, apparent destruction or com-
pression of the cortical zone, and destruction of the corti-
comedullary junction (Fig. 3 A). The medullary expansion
appeared to be driven by endothelial proliferation or by
vascular ectasia and fibrocyte proliferation. The endothelial
cells lining medullary vessels appeared to be activated, in a
fashion resembling vascular endothelium in the setting of
inflammation. The expanded medullary zone contained
atypical cells with prominent nuclear inclusions (Cowdry
type A; Fig. 3 C). Immunohistochemical staining with an
mAb specific for the p41 early protein of HHV-6 demon-
strated that most of these atypical cells were infected (Fig.
3 D). Double-staining analysis showed that virtually all the
infected cells were CD31, albeit with varying degrees of
intensity (Fig. 3 E). By contrast, double-label staining with
CD68 did not indicate a tropism of HHV-6AGS for mac-
rophages in this model (Fig. 3 F).
Cytofluorimetric Analysis of Thymocyte Subpopulations from
Thy/Liv Implants Infected with HHV-6AGS. To evaluate the
effects of viral replication on different thymocyte subpopu-
lations, we performed quantitative flow cytometry on total
thymocyte suspensions obtained from six different cohorts
of SCID-hu Thy/Liv mice in three independent experi-
ments. HHV-6AGS–infected implants were harvested 4, 7,
11, 14, and 27 d after inoculation and examined for expres-
sion of CD3, CD4, and CD8. 4 and 7 d after inoculation,
Figure 3. Histopathology of
HHV-6AGS–infected Thy/Liv im-
plants. (A) Severe thymocyte
depletion associated with prolif-
eration of granulation tissue in an
implant harvested 14 d after
inoculation with HHV-6AGS
(H&E; original magnification:
340). (B) Typical appearance of
a mock-infected Thy/Liv im-
plant (H&E; original magnifica-
tion: 340). (C) Cytopathic ef-
fects induced by HHV-6AGS.
Atypical giant cells with promi-
nent nuclear viral inclusions
(Cowdry type A) (H&E; original
magnification: 31,000). (D) Im-
munohistochemical staining with
9A5D12, an mAb specific for the
p41 early protein of HHV-6. In-
fected cells are scattered through-
out the implant and include sev-
eral large atypical cells (original
magnification: 3100). (E) Dou-
ble staining with CD3 (DAB)
and 9A5D12 (Vector Red). All
the cells that are positive for
HHV-6 also coexpress CD3
(original magnification: 31,000).
(F) Double staining with an mAb
to the macrophage marker CD68
(DAB) and to the p41 early pro-
tein of HHV-6 (9A5D12, Vec-
tor Red) (original magnifica-
tion: 31,000).
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the percentages of the different thymocyte subsets were un-
changed compared with mock-infected implants (Table I).
The earliest detectable phenotypic change was a reduced
percentage of ITTPs at day 11 (P , 0.05), a time at which
the percentages of the other thymocyte subpopulations
were not yet significantly changed (Table I). By day 14, a
reduction in the percentage of live thymocytes, identified
by forward- and side-scatter profiles, was observed (Table I).
At this time point, ITTPs remained significantly depleted
(P , 0.01), and there was also a reduction in the percent-
age of DP thymocytes (P , 0.001) and an increase in the
percentage of SP4 (P , 0.05) and SP8 (P , 0.01) thy-
mocytes (Table I). By day 27, most of the thymocytes were
dead or dying, and it was no longer possible to analyze the
different subpopulations (Table I).
Cellular Tropism of HHV-6AGS in Thy/Liv Implants. To
study the cellular tropism of HHV-6AGS in Thy/Liv im-
plants, the distribution of viral DNA was quantitated in the
different subpopulations of thymocytes as a function of
time after inoculation. Total thymocytes were harvested at
4, 7, 11, and 14 d after inoculation and sorted into DP,
SP4, SP8, and ITTP subpopulations. The viral load in each
subpopulation was measured by quantitative PCR (Table
II). At day 4 after inoculation, viral DNA was detectable in
ITTPs but was less abundant or undetectable in the other
subpopulations. By day 7, HHV-6 DNA was detectable in
all the thymocyte subsets, but was significantly more abun-
dant in ITTPs (P , 0.05) and remained so at 11 and 14 d
after inoculation. No HHV-6 DNA was detected in any of
the thymocyte subpopulations from Thy/Liv implants in-
fected with UV-inactivated viral stock (data not shown).
Replication of HHV-6BPL-1 in Human Thy/Liv Implants.
To study the effects of HHV-6 subgroup B on Thy/Liv
implants, six SCID-hu Thy/Liv mice were inoculated with
104 TCID50 of strain PL-1 (a primary isolate passaged in
vitro only twice), or mock infected with cell culture me-
Table I. Effects of HHV-6AGS Replication on Thymocyte Subpopulations
Days after
inoculation No. of mice
Live
thymocytes* DP‡ SP4‡ SP8‡ ITTP‡
% % % % %
Mock 21 70 6 1.5 86 6 0.6 8.7 6 0.4 4.4 6 0.3 1.4 6 0.1
4 3 76 6 0.8 87 6 1.5 8.2 6 1.2 4.6 6 0.4 0.8 6 0.1
7 3 64 6 6.6 87 6 2.2 6.9 6 1.3 5.2 6 0.9 0.9 6 0.4
11 4 50 6 8.6 85 6 0.9 9.5 6 1.0 4.6 6 0.3 0.3 6 0.1§
14 19 53 6 4.8§ 79 6 1.5i 12 6 1.1§ 6.5 6 0.4i 1.0 6 0.2§
27 8 6.7 6 3.9i ND ND ND ND
Thy/Liv implants were harvested 4, 7, 11, 14, and 27 d after direct intrathymic injection of HHV-6AGS or mock injection of UV-inactivated viral
stock (n 5 9) or culture medium (n 5 12) (Mock) and assessed for distribution of thymocyte subpopulations by flow cytometry.
*The percentage of live thymocytes was determined by forward- and side-scatter characteristics.
‡Thymocyte subsets were quantified as a percentage of total live thymocytes. Data are expressed as mean 6 SEM of three independent experiments
using six different cohorts of SCID-hu Thy/Liv mice.
§P , 0.01 vs. mock-infected implants.
iP , 0.001 vs. mock-infected implants.
Table II. Cellular Tropism of HHV-6AGS in Thy/Liv Implants
Days after
inoculation
No. of
mice
HHV-6 DNA (copies/103 cells)*
DP SP4 SP8 ITTP
4 3 Undetectable‡ Undetectable‡ 20 6 20 123 6 91
7 3 23 6 23 497 6 304 140 6 72 1,500 6 863§
11 3 280 6 181 Undetectable‡ 30 6 30 6,840 6 4,645i
14 7 32 6 17 33 6 18 45 6 22 599 6 323i
Thy/Liv implants were harvested 4, 7, 11, and 14 d after direct intrathymic injection of HHV-6AGS. DP, SP4, SP8 thymocytes, and ITTPs were
then sorted, and HHV-6 DNA load was assessed by quantitative PCR.
*Mean viral copies/103 cells 6 SEM. Results are shown from two independent experiments in three different cohorts of SCID-hu Thy/Liv mice.
‡Less than 10 copies/103 cells.
§P , 0.05 vs. DP and SP8 thymocytes.
iP , 0.05 vs. DP, SP4, and SP8 thymocytes.
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dium. Mice were killed 10 d after inoculation, and the im-
plants were removed. Quantitative PCR analysis revealed
efficient replication of HHV-6BPL-1 (mean viral load of
z2,200 copies/103 cells) similar to that found in HHV-
6AGS–infected implants (Table III). The effects of HHV-
6BPL-1 replication on thymocyte subpopulations were as-
sessed by flow cytometry. As observed for strain GS at a
similar time point (day 11; Table I), the main effect of
HHV-6BPL-1 on thymocyte subpopulations was a reduction
in the percentage of ITTPs (Table III). At this relatively
early time point, the percentage of live thymocytes was also
decreased (Table III).
Discussion
This study provides the first evidence that HHV-6 can
replicate in the human thymus in vivo, leading to a pro-
gressive destruction of the organ. The severity of the le-
sions caused by HHV-6 in Thy/Liv implants supports the
hypothesis that this virus may be immunosuppressive, as
previously suggested by its tropism for CD41 T cells and
by the severe cytopathic effects it exerts on infected cells in
vitro. Interestingly, the histological lesions we observed in
HHV-6–infected Thy/Liv implants are similar to those re-
cently described in the thymus of an HIV-1–negative in-
fant with immunosuppression associated with widespread
HHV-6 infection (5), suggesting that SCID-hu Thy/
Liv mice may reproduce the pathological mechanisms of
HHV-6 infection in humans. However, despite the high
prevalence of HHV-6 infection in the human population,
only rare cases of putative HHV-6–related immunosup-
pression have been reported to date. It remains to be deter-
mined whether thymic infection by HHV-6 is an uncom-
mon occurrence or, alternatively, whether its pathological
consequences in vivo may be attenuated by host immune
responses.
The experiments reported here were focused mainly on
HHV-6AGS, but limited studies with a subgroup B virus
(PL-1) indicate that viruses of both subgroups can replicate
in the Thy/Liv organ and induce cytopathicity. Clinical
and epidemiological studies have shown an association of
both subgroup A and B viruses with immunodeficiency (2),
although subgroup B viruses have also been frequently iso-
lated from the general population of nonimmunocompro-
mised subjects. Coinfection by A and B strains was also
documented in the infant with HHV-6–associated immu-
nosuppression mentioned above (5). Further work will be
required, both in humans and in SCID-hu Thy/Liv mice,
to determine whether there are any intrinsic differences be-
tween the two HHV-6 subgroups in their propensity to in-
duce immunosuppression in vivo.
The immunohistochemical detection of the CD3 anti-
gen on the majority of the infected cells suggests that ma-
ture thymocytes can be infected by HHV-6 in vivo. How-
ever, the early and persistent depletion of ITTPs indicates
that HHV-6 has a particular tropism for these immature
cells. Indeed, quantitative PCR on sorted thymocyte sub-
populations showed a markedly higher HHV-6 DNA load
in ITTPs than in the other subpopulations. ITTPs are a rel-
atively rare but rapidly dividing subpopulation that repre-
sents an early step of thymocyte maturation and gives rise
to DP thymocytes and their mature SP progeny (21). De-
struction of ITTPs may result in the generalized suppres-
sion of thymopoiesis and ultimately in the depletion of the
thymus.
The thymus is the primary site of T lymphocyte devel-
opment in utero and in early life. Although its activity di-
minishes progressively with age, this organ may still be
functional in adults and, during conditions of severe T cell
depletion (including HIV-1 infection), it may play an im-
portant role in maintaining and reconstituting the periph-
eral immune system (29–32). Accordingly, abundant thy-
mic tissue has been detected by chest computed tomography
in HIV-1–seropositive adults, suggesting that thymic func-
tion may be enhanced, by a compensatory mechanism, in
some HIV-1–infected patients (32). However, persistent
thymic function in an adult could be quickly abolished by
thymic infection with HIV or other T cell–tropic viruses
such as HHV-6.
Because of its tropism for CD41 T lymphocytes and its
positive interactions in vitro with HIV-1, HHV-6 has been
suggested as a possible cofactor in AIDS (6). This hypothe-
sis is supported by clinical evidence of active and widespread
HHV-6 infection in symptomatic AIDS patients (7–9).
Table III. Replication of HHV-6BPL-1 in Thy/Liv Implants and Effects on Thymocyte Subpopulations
Virus
No. of
mice HHV-6 DNA* Live thymocytes‡ DP§ SP4§ SP8§ ITTP§
% % % % %
Mock 2 Undetectable 73 6 9.1 82 6 0.4 10.4 6 0.1 6.4 6 0.1 1.2 6 0.1
HHV-6BPL-1 4 2,169 6 552 62 6 2.5 82 6 0.4 8.8 6 0.3 8.1 6 0.3 0.3 6 0.02
Thy/Liv implants were harvested 10 d after direct intrathymic injection of HHV-6BPL-1 or mock injection of culture medium. Viral replication was
assessed by quantitative PCR on total thymocyte suspensions, and the distribution of thymocyte subpopulations was studied by flow cytometry.
*Mean viral copies/103 cells 6 SEM.
‡The percentage of live thymocytes was determined by forward- and side-scatter characteristics.
§Thymocyte subsets were quantified as a percentage of total live thymocytes. Data are expressed as mean 6 SEM.
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HHV-6 infects human thymocytes in vitro (3) and has
been detected in the thymus in vivo (5, 33). Thus, HHV-6
infection of the thymus may play a role in the immuno-
deficiency associated with HIV-1 infection. However, it is
technically difficult to study the thymus in humans, and no
reports are currently available on the presence of thymic
HHV-6 infection in patients with HIV disease. The SCID-hu
Thy/Liv mouse model, carrying a human graft that is mor-
phologically and functionally equivalent to the human thy-
mus, provides a unique system to study the pathogenesis of
HHV-6 and HIV-1 infections in vivo (10–14). Interest-
ingly, some chemokine receptor CXCR4-using strains of
HIV-1, like NL4-3, suppress thymopoiesis in SCID-hu
Thy/Liv mice by direct infection and destruction of ITTPs
(11). The tropism of HHV-6 and HIV-1 for the same thymo-
cyte subset raises the possibility of synergistic interactions in
the thymic environment. Future studies of coinfection with
HHV-6 and HIV-1 in SCID-hu Thy/Liv mice may pro-
vide important insights into the role of HHV-6 in HIV-1
disease.
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